INO Stock News & Catalysts – Inovio Pharmaceuticals

FEATURED

INOVIO Announces Pricing of Approximately $75 Million Public Offering

PLYMOUTH MEETING, Pa., Nov. 5, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from

Summary

Nov 5, 2026, 11:18 PM ·PRNewswire

RECENT

INOVIO Announces Proposed Public Offering of its Common Stock

Nov 5, 2026, 4:01 PM ·PRNewswire

INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026

PLYMOUTH MEETING, Pa., Nov. 2, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases,

Nov 2, 2026, 4:15 PM ·PRNewswire

INOVIO to Participate in Upcoming Scientific Conferences

Nov 2, 2026, 4:01 PM ·PRNewswire

INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)

INOVIO delivers a new nonsurgical treatment option with a broad indication for adults living with RRP, a rare and debilitating disease that often requires surgeryVOCERYQ™ is a plasmid DNA-based immunotherapy that

Oct 30, 2026, 6:01 PM ·PRNewswire

INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

PLYMOUTH MEETING, Pa., Oct. 20, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people

Oct 20, 2026, 4:05 PM ·PRNewswire

INOVIO to Participate in Upcoming Investor Conferences

PLYMOUTH MEETING, Pa., Sept. 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases,

Sep 1, 2026, 4:05 PM ·PRNewswire

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act

Aug 12, 2026, 4:05 PM ·PRNewswire

INOVIO to Report Second Quarter Financial Results on August 12, 2026

PLYMOUTH MEETING, Pa., Aug. 4, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases,

Aug 4, 2026, 4:05 PM ·PRNewswire

INOVIO Announces Pricing of $20.0 Million Public Offering

PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people

Jul 29, 2026, 8:53 PM ·PRNewswire

INOVIO Announces Proposed Public Offering

Jul 29, 2026, 4:01 PM ·PRNewswire

Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK, June 4, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) breached their fiduciary

Jun 4, 2026, 4:37 PM ·PRNewswire

Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) breached their

Jun 2, 2026, 12:09 PM ·Globe Newswire

INOVIO to Participate in Upcoming Scientific and Investor Conferences

PLYMOUTH MEETING, Pa., May 28, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer

May 28, 2026, 8:05 AM ·PRNewswire

Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China

Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidateApolloBio's new clinical results further highlight the

May 21, 2026, 4:05 PM ·PRNewswire

Inovio Pharmaceuticals, Inc. INO · News